---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-22-069168"
form_type: "8-K"
ticker: "OCUL"
cik: "0001393434"
company_name: "OCULAR THERAPEUTIX, INC"
filed_at: "2022-06-08T23:59:59+00:00"
generated_at: "2026-06-25T03:28:21.053514+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# President/CMO Michael Goldstein to depart June 30; Rabia Ozden named new CMO

## Summary
- Michael Goldstein, President Ophthalmology and CMO, leaves OCUL on June 30, 2022.
- Rabia Gurses Ozden, SVP Clinical Development, becomes Chief Medical Officer on July 1, 2022.
- Goldstein enters consulting agreement from July 2022 to June 2023, renewable to 2026, at $6,000/month.
- Consulting agreement includes non-competition and non-solicitation provisions.

## SEC filing metadata
- accession: 0001104659-22-069168
- form_type: 8-K
- ticker: OCUL
- cik: 0001393434
- company_name: OCULAR THERAPEUTIX, INC
- filed_at: 2022-06-08T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1393434/000110465922069168/0001104659-22-069168-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1393434/000110465922069168/tm2217977d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-22-069168
- JSON: https://secwatch.observer/filing/0001104659-22-069168.json
- Plain text: https://secwatch.observer/filing/0001104659-22-069168.txt

## Key facts
- Executive change
  Michael Goldstein departed as President, Ophthalmology and Chief Medical Officer at OCULAR THERAPEUTIX, INC.
  - Action: departed
  - Role: President, Ophthalmology and Chief Medical Officer
  source text: On June 3, 2022, Michael Goldstein, M.D., President, Ophthalmology and Chief Medical Officer of Ocular Therapeutix, Inc. (the “Company”) and the Company mutually agreed that Dr. Goldstein would depart the Company to pursue other business opportunities, effective June 30, 2022 (the “Separation Date”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465922069168/0001104659-22-069168-index.htm
- Executive change
  Rabia Gurses Ozden was appointed as Chief Medical Officer at OCULAR THERAPEUTIX, INC.
  - Action: appointed
  - Role: Chief Medical Officer
  source text: In connection with his departure, Rabia Gurses Ozden, M.D., Senior Vice President, Clinical Development of the Company, has agreed to assume the role of Chief Medical Officer of the Company, effective on July 1, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1393434/000110465922069168/0001104659-22-069168-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.